Segunda línea de tratamiento de pacientes con NSCLC PD-L1 positivo: - page 21

30% PD-L1> 50%

Reck et al, ESMO 2016

SEO Version

Warning.

You are currently viewing the SEO version of !text.
It has a number of design and functionality limitations.

We recommend viewing the Flash version or the basic HTML version of this publication.

1...,11,12,13,14,15,16,17,18,19,20 22,23,24,25,26,27,28,29,30,31,...33